ArticlePatient preference and adherence2025
Application of Polidocanol Foam Injection Sclerotherapy in Patients with Antithrombotic Therapy Combined with Mixed Hemorrhoid Bleeding: A Retrospective Single-Center Case Series and Narrative Review (with Video).
Article in Patient preference and adherence, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: For patients with antithrombotic therapy combined with mixed hemorrhoid bleeding, the contradiction between antithrombotic and hemostatic treatments often requires surgical intervention. However, multi-country guidelines recommend the use of injection sclerotherapy (IST), but there is little research on the application of polidocanol foam IST. The purpose of this study is to explore the retrospective single-center case series experience of polidocanol foam IST in those patients and review the related literature. Patients and Methods: From March 2018 to May 2023, we retrospectively analyzed the clinical data of 7 patients with mixed hemorrhoid bleeding in the General Surgery Department of Yangpu Hospital affiliated with Tongji University. These patients all received antithrombotic treatment and their bleeding could not be stopped by conservative treatment. Finally, they all received polidocanol foam IST. We summarized the single-center clinical application experience of polidocanol foam IST in those patients. Through a literature search, the related literature concerning the application of polidocanol foam IST in patients with antithrombotic therapy combined with mixed hemorrhoid bleeding were reviewed. Results: Seven patients were successfully treated with polidocanol foam IST, and the bleeding stopped. The operation time ranged from 10-30 minutes, and no serious complications occurred. At the 4-week postoperative follow-up evaluation, none of the patients had bleeding again, and hemoglobin significantly increased (106.0±17.4 g/L vs 70.9±19.7 g/L, Conclusion: Polidocanol foam IST is a relatively safe and effective method for patients receiving antithrombotic therapy combined with mixed hemorrhoid bleeding. However, larger multicenter prospective studies are needed before this is the preferred treatment for such patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.